Literature DB >> 15585514

The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes.

Bryan M Curtis1, Pietro Ravani, F Malberti, Fiona Kennett, Paul A Taylor, Ognjenka Djurdjev, Adeera Levin.   

Abstract

BACKGROUND: This two country case control study of incident dialysis patients evaluates the outcomes of patients exposed to formalized multi-disciplinary clinic (MDC) programmes vs standard nephrologist care.
METHODS: Patients commencing dialysis in two centres (Vancouver, Canada and Cremona, Italy) were evaluated at and after dialysis start, as a function of MDC exposure vs nephrologist care alone. Only chronic kidney disease patients, with longer than 3 months of exposure to nephrology care, who had not previously received kidney replacement therapy were included. Study outcomes included laboratory parameters and survival. The MDC was similar in both countries and average exposure was 6-8 h per patient-year, as compared to 2-4 h for standard care. All patients had equal access to resources prior to dialysis and with respect to dialysis start, as all had been referred to the same local nephrology practices.
RESULTS: During the evaluation period 288 patients commenced dialysis after receiving more than 3 months nephrology care prior to dialysis. There were no major demographic differences between the cohorts. Mean duration of nephrology care prior to dialysis was 42 months, and dialysis was initiated at similar low glomerular filtration rate (GFR), though statistically significantly different (7.0 and 8.4 ml/min/m2, P = 0.001). The MDC patients had higher haemoglobin (102 vs 90 g/l, P<0.0001), albumin (37.0 vs 34.8 g/l, P = 0.002) and calcium levels (2.29 vs 2.16 mmol/l, P<0.0001) at dialysis start. Survival was significantly better in the MDC group demonstrated by Kaplan-Meier analysis (P = 0.01). Cox proportional hazards analysis demonstrated standard nephrology clinic vs MDC attendance was a statistically significant independent predictor of death (hazards ratio = 2.17, 95% confidence interval 1.11-4.28) after adjusting for other variables known to impact outcomes.
CONCLUSIONS: This analysis of outcomes in two different countries suggests that despite equal and long exposure to nephrology care prior to dialysis, there appears to be an association of survival advantage for those patients exposed to formalized clinic care in addition to standard nephrologist follow-up. While other known predictors of survival such as adequacy of dialysis and severity of illness measures were not included in the model, those parameters require time on dialysis to be accumulated. Thus, the data do suggest that knowledge of patient status at the time of dialysis start is important. Further research is needed to determine which specific components of care both prior to dialysis and after its commencement are most important with respect to outcomes.

Entities:  

Mesh:

Year:  2004        PMID: 15585514     DOI: 10.1093/ndt/gfh585

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  44 in total

1.  The effect of a multidisciplinary care clinic on the outcomes in pediatric chronic kidney disease.

Authors:  Salma Ajarmeh; Lee Er; Genevieve Brin; Ognjenka Djurdjev; Janis M Dionne
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

2.  Multidisciplinary team care may slow the rate of decline in renal function.

Authors:  Elizabeth A Bayliss; Bharati Bhardwaja; Colleen Ross; Arne Beck; Diane M Lanese
Journal:  Clin J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 8.237

3.  Why multidisciplinary clinics should be the standard for treating chronic kidney disease.

Authors:  Guido Filler; Steven E Lipshultz
Journal:  Pediatr Nephrol       Date:  2012-07-04       Impact factor: 3.714

Review 4.  Epidemiology of peritoneal dialysis: a story of believers and nonbelievers.

Authors:  Norbert Lameire; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2009-12-15       Impact factor: 28.314

5.  A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial.

Authors:  Brendan J Barrett; Amit X Garg; Ron Goeree; Adeera Levin; Anita Molzahn; Claudio Rigatto; Joel Singer; George Soltys; Steven Soroka; Dieter Ayers; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

6.  Person-Centered Integrated Care for Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Pim P Valentijn; Fernando Abdalla Pereira; Marinella Ruospo; Suetonia C Palmer; Jörgen Hegbrant; Christina W Sterner; Hubertus J M Vrijhoef; Dirk Ruwaard; Giovanni F M Strippoli
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-09       Impact factor: 8.237

7.  Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan.

Authors:  Salah M AbuRuz; Yazan Alrashdan; Anan Jarab; Deema Jaber; Izzat A Alawwa
Journal:  Int J Clin Pharm       Date:  2013-07-25

8.  Clinical outcomes in patients with chronic kidney disease: a 5-year retrospective cohort study at a University Hospital in Japan.

Authors:  Tetsuri Yamashita; Takumi Yoshida; Tetsuya Ogawa; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-07-30       Impact factor: 2.801

9.  Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: a case series.

Authors:  Paul Komenda; Nadia Zalunardo; Shelley Burnett; Janet Love; Christpher Buller; Paul Taylor; John Duncan; Ogjenenka Djurdjev; Adeera Levin
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

10.  Structured clinical follow-up for CKD stage 5 may safely postpone dialysis.

Authors:  Pietro Dattolo; Stefano Michelassi; Marco Amidone; Marco Allinovi; Lorenzo Vignali; Giulia Antognoli; Rosa Roperto; Francesco Pizzarelli
Journal:  J Nephrol       Date:  2014-07-18       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.